3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer

Blais, Lucie; Desgagné, Alain et LeLorier, Jacques (2000). « 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer ». Archives of Internal Medicine, 160(15), p. 2363.

Fichier(s) associé(s) à ce document :
Télécharger (604kB)


Background During the past 15 years there has been an exponential increase in the number of prescriptions for lipid-lowering drugs. Uncertainties remain about the long-term impact of these medications on cancer, which is particularly bothersome given that the duration of these treatments may extend for several decades. Objective To explore the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and cancer incidence. Methods Using the administrative health databases of the Régie de l'Assurance-Maladie du Québec we performed a nested case-control study. We selected a cohort of 6721 beneficiaries of the health care plan of Quebec who were free of cancer for at least 1 year at cohort entry, 65 years and older, and treated with lipid-modifying agents. Cohort members were selected between 1988 and 1994 and were followed up for a median period of 2.7 years. From the cohort, 542 cases of first malignant neoplasm were identified, and 5420 controls were randomly selected. Users of HMG-CoA reductase inhibitors were compared with users of bile acid–binding resins as to their risk of cancer. Specific cancer sites were also considered. Results Users of HMG-CoA reductase inhibitors were found to be 28% less likely than users of bile acid–binding resins to be diagnosed as having any cancer (rate ratio, 0.72; 95% confidence interval, 0.57-0.92). All specific cancer sites under study were found to be not or inversely associated with the use of HMG-CoA reductase inhibitors. Conclusion The results of our study provide some degree of reassurance about the safety of HMG-CoA reductase inhibitors.

Type: Article de revue scientifique
Mots-clés ou Sujets: hydroxymethylglutaryl coenzyme A reductase inhibitor, cancer incidence, cancer localization, cancer risk, carcinogenicity, controlled study, drug effect, drug safety, female, follow up, human, major clinical study, male
Unité d'appartenance: Faculté des sciences > Département de mathématiques
Déposé par: Alain Desgagné
Date de dépôt: 19 avr. 2016 20:07
Dernière modification: 27 avr. 2016 18:33
Adresse URL : http://archipel.uqam.ca/id/eprint/8198


Voir les statistiques sur cinq ans...